05.04.26 -- Cell And Gene Therapy CDMOs: On The Path To $75 Billion In Services?

Early, collaborative CDMO partnerships optimize complex AAV development, enhancing manufacturability and reducing risks to shorten timelines more effectively than traditional transactional models.

Enzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.

Navigating PFS selection requires balancing complex regulatory requirements and supply chain logistics. Adopting an integrated system approach provides unified data and streamlined documentation.

Learn how digital maturity and compliance excellence are reshaping CDMO competitiveness, as well as strategies that strengthen performance and accelerate tech transfers.

Capital constraints are reshaping CDMO and pharma strategies, driving selective M&A, prioritizing partnerships, and enforcing financial discipline amid tighter investment conditions.

Uncover the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of every day, manufacturing operational excellence.

Discover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Explore the strategy used to balance speed, risk mitigation, and the highest quality standards.

Read how one family's race against time led to the creation of a groundbreaking gene therapy for their daughter, just 14 months after her ultra-rare disease diagnosis.

Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.